BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22333689)

  • 1. Diagnostic value of antibodies to modified citrullinated vimentin in early rheumatoid arthritis.
    Sizova L
    Hum Immunol; 2012 Apr; 73(4):389-92. PubMed ID: 22333689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X; Jia R; Zhao J; Li Z
    J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
    Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
    J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
    Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
    Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
    Dejaco C; Klotz W; Larcher H; Duftner C; Schirmer M; Herold M
    Arthritis Res Ther; 2006; 8(4):R119. PubMed ID: 16859519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.
    Nicaise-Roland P; Nogueira L; Demattei C; de Chaisemartin L; Rincheval N; Cornillet M; Grootenboer-Mignot S; Dieudé P; Dougados M; Cantagrel A; Meyer O; Serre G; Chollet-Martin S
    Ann Rheum Dis; 2013 Mar; 72(3):357-62. PubMed ID: 22580581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
    Bang H; Egerer K; Gauliard A; Lüthke K; Rudolph PE; Fredenhagen G; Berg W; Feist E; Burmester GR
    Arthritis Rheum; 2007 Aug; 56(8):2503-11. PubMed ID: 17665451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.
    Damjanovska L; Thabet MM; Levarth EW; Stoeken-Rijsbergen G; van der Voort EI; Toes RE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2010 Apr; 69(4):730-2. PubMed ID: 19451136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide.
    El-Barbary AM; Kassem EM; El-Sergany MA; Essa SA; Eltomey MA
    J Rheumatol; 2011 May; 38(5):828-34. PubMed ID: 21362765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
    Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
    Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.